Feasibility Study on Combination Chemotherapy Using Nogitecan Hydrochloride (topotecan) and Cisplatin for Patients with Metastatic, Persistent, or Recurrent Uterine Cervical Cancer.

The standard chemotherapeutic regimen for stage IVB, persistent, or recurrent uterine cervical cancer is platinum-based combination chemotherapy such as cisplatin (CDDP)/paclitaxel and CDDP/nogitecan hydrochloride (NGT, topotecan). Because it is unclear whether the CDDP/NGT combination chemotherapy is tolerable for Japanese patients, we conducted the present study to assess the feasibility of CDDP/NGT combination chemotherapy.